These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 33480997)
1. Compatibility of Evolutionary Responses to Constituent Antibiotics Drive Resistance Evolution to Drug Pairs. Jahn LJ; Simon D; Jensen M; Bradshaw C; Ellabaan MMH; Sommer MOA Mol Biol Evol; 2021 May; 38(5):2057-2069. PubMed ID: 33480997 [TBL] [Abstract][Full Text] [Related]
2. Modified Antibiotic Adjuvant Ratios Can Slow and Steer the Evolution of Resistance: Co-amoxiclav as a Case Study. Allen RC; Brown SP mBio; 2019 Sep; 10(5):. PubMed ID: 31530673 [TBL] [Abstract][Full Text] [Related]
3. Prediction of resistance development against drug combinations by collateral responses to component drugs. Munck C; Gumpert HK; Wallin AI; Wang HH; Sommer MO Sci Transl Med; 2014 Nov; 6(262):262ra156. PubMed ID: 25391482 [TBL] [Abstract][Full Text] [Related]
4. Acceleration and suppression of resistance development by antibiotic combinations. Suzuki S; Horinouchi T; Furusawa C BMC Genomics; 2017 Apr; 18(1):328. PubMed ID: 28446153 [TBL] [Abstract][Full Text] [Related]
5. Predictable properties of fitness landscapes induced by adaptational tradeoffs. Das SG; Direito SO; Waclaw B; Allen RJ; Krug J Elife; 2020 May; 9():. PubMed ID: 32423531 [TBL] [Abstract][Full Text] [Related]
6. Quantifying the Determinants of Evolutionary Dynamics Leading to Drug Resistance. Chevereau G; Dravecká M; Batur T; Guvenek A; Ayhan DH; Toprak E; Bollenbach T PLoS Biol; 2015; 13(11):e1002299. PubMed ID: 26581035 [TBL] [Abstract][Full Text] [Related]
7. Antibiotic interactions shape short-term evolution of resistance in E. faecalis. Dean Z; Maltas J; Wood KB PLoS Pathog; 2020 Mar; 16(3):e1008278. PubMed ID: 32119717 [TBL] [Abstract][Full Text] [Related]
8. High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance. Wambaugh MA; Shakya VPS; Lewis AJ; Mulvey MA; Brown JCS PLoS Biol; 2017 Jun; 15(6):e2001644. PubMed ID: 28632788 [TBL] [Abstract][Full Text] [Related]
9. When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. Pena-Miller R; Laehnemann D; Jansen G; Fuentes-Hernandez A; Rosenstiel P; Schulenburg H; Beardmore R PLoS Biol; 2013; 11(4):e1001540. PubMed ID: 23630452 [TBL] [Abstract][Full Text] [Related]
10. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Kim S; Lieberman TD; Kishony R Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14494-9. PubMed ID: 25246554 [TBL] [Abstract][Full Text] [Related]
11. Time-programmable drug dosing allows the manipulation, suppression and reversal of antibiotic drug resistance in vitro. Yoshida M; Reyes SG; Tsuda S; Horinouchi T; Furusawa C; Cronin L Nat Commun; 2017 Jun; 8():15589. PubMed ID: 28593940 [TBL] [Abstract][Full Text] [Related]
12. Effect of drug combinations on the kinetics of antibiotic resistance emergence in Escherichia coli CFT073 using an in vitro hollow-fibre infection model. Garimella N; Zere T; Hartman N; Gandhi A; Bekele A; Li X; Stone H; Sacks L; Weaver JL Int J Antimicrob Agents; 2020 Apr; 55(4):105861. PubMed ID: 31838036 [TBL] [Abstract][Full Text] [Related]
13. A population genomics approach to exploiting the accessory 'resistome' of Goldstone RJ; Smith DGE Microb Genom; 2017 Apr; 3(4):e000108. PubMed ID: 28785420 [TBL] [Abstract][Full Text] [Related]
14. Changes in Intrinsic Antibiotic Susceptibility during a Long-Term Evolution Experiment with Escherichia coli. Lamrabet O; Martin M; Lenski RE; Schneider D mBio; 2019 Mar; 10(2):. PubMed ID: 30837336 [TBL] [Abstract][Full Text] [Related]
15. Drug interactions modulate the potential for evolution of resistance. Michel JB; Yeh PJ; Chait R; Moellering RC; Kishony R Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14918-23. PubMed ID: 18815368 [TBL] [Abstract][Full Text] [Related]
17. Using experimental evolution to identify druggable targets that could inhibit the evolution of antimicrobial resistance. Mehta HH; Prater AG; Shamoo Y J Antibiot (Tokyo); 2018 Feb; 71(2):279-286. PubMed ID: 28928474 [TBL] [Abstract][Full Text] [Related]
18. Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections. Copp JN; Pletzer D; Brown AS; Van der Heijden J; Miton CM; Edgar RJ; Rich MH; Little RF; Williams EM; Hancock REW; Tokuriki N; Ackerley DF mBio; 2020 Sep; 11(5):. PubMed ID: 32934086 [TBL] [Abstract][Full Text] [Related]